Analysts Are Bullish on Top Healthcare Stocks: Venus Concept (VERO), Disc Medicine (IRON)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Venus Concept (VERO – Research Report), Disc Medicine (IRON – Research Report) and Gracell Biotechnologies (GRCL – Research Report) with bullish sentiments.

Venus Concept (VERO)

BTIG analyst Marie Thibault maintained a Buy rating on Venus Concept today and set a price target of $12.00. The company’s shares closed last Monday at $3.66, close to its 52-week low of $2.25.

According to TipRanks.com, Thibault is a 4-star analyst with an average return of 4.2% and a 38.8% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Irhythm Technologies, and Edwards Lifesciences.

Venus Concept has an analyst consensus of Moderate Buy, with a price target consensus of $12.00.

See today’s best-performing stocks on TipRanks >>

Disc Medicine (IRON)

In a report released today, Rami Katkhuda from LifeSci Capital maintained a Buy rating on Disc Medicine, with a price target of $37.00. The company’s shares closed last Monday at $31.81, close to its 52-week high of $35.03.

According to TipRanks.com, Katkhuda is a 1-star analyst with an average return of -4.9% and a 41.9% success rate. Katkhuda covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, Calliditas Therapeutics, and Eledon Pharmaceuticals.

Currently, the analyst consensus on Disc Medicine is a Strong Buy with an average price target of $38.29.

Gracell Biotechnologies (GRCL)

In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on Gracell Biotechnologies, with a price target of $12.00. The company’s shares closed last Monday at $2.18.

According to TipRanks.com, Bodnar has 0 stars on 0-5 stars ranking scale with an average return of -9.9% and a 33.0% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as Acrivon Therapeutics, Inc., Olema Pharmaceuticals, and Context Therapeutics.

Currently, the analyst consensus on Gracell Biotechnologies is a Moderate Buy with an average price target of $9.50.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on VERO:

• Venus Concept Announces First Quarter of Fiscal Year 2023 Financial Results
• Venus Concept Announces 1-for-15 Reverse Stock Split
• Venus Concept to Release First Quarter of Fiscal Year 2023 Financial Results on May 15, 2023
• Venus Concept downgraded to Hold from Buy at Maxim
• Venus Concept price target lowered to $2.20 from $3.25 at Ladenburg